An essential component of this technological rollout is the AI-driven de novo antibody sequence generation service. This ...
Creative Biolabs highlights the growing importance of antibody engineering and conversion strategies in advancing ...
The US National Science Foundation (NSF) has launched an investment programme to advance scientific community datasets and ...
The deadline for abstract submission (late-breaking posters) is coming up on 30 th July. The deadline for late registration ...
Beckman Coulter Diagnostics, a specialist in clinical diagnostics and a Danaher company, has received CE Mark under IVDR for its Acess p-Tau217 assay, a blood test designed to support the clinical ...
CDMO partner Freudenberg Medical recently launched CleanAssure, an ISO Class 5 controlled cleanroom for sterile single-use assemblies. The cleaning and sterilisation service supports biopharmaceutical ...
Biotechnology company Nuclera has introduced an antibody screening service to enable quick access to high-quality proteins and advance AI-driven discovery. “Antibodies are one of the most important ...
Women’s health medical technology company Calla Lily Clinical Care has dosed the first patients in the Freedom clinical trial. The study is evaluating 400mg progesterone Callavid in patients diagnosed ...
Servier, an independent international pharmaceutical company governed by a foundation, and n-Lorem Foundation, a non-profit organisation established to provide experimental medicines to patients with ...
Recombinant technology specialist Sino Biological has launched the XPressMAX Cell-Free Protein Synthesis Kit (Cat#: CFKIT02). The solution is designed to supercharge AI-driven high-throughput ...
AndzonBio2 has signed agreements with the Alborada Drug Discovery Institute (ADDI) at the University of Cambridge and Cambridge Enterprise to advance a new class of therapeutics targeting ...
Lundbeck will be presenting its research at the 2026 Alzheimer’s and Parkinson’s Disease conference Lundbeck has shared that new data from a Phase 1b proof-of-mechanism trial of Lu AF28996, a novel ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results